Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

500
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
500
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

448
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
448
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Worldwide evaluation of Clinical Practice Strategies (CliPS) for lung involvement in Still's disease within the JIR-CliPS network: a COST action.

Rheumatology advances in practice·2025
Same author

Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients-A Comprehensive Review.

Journal of fungi (Basel, Switzerland)·2025
Same author

[New developments in juvenile arthritis].

Revue medicale suisse·2025
Same author

Inflammatory Choroidal Neovascularization in Pediatric Uveitis: A Case Series.

Klinische Monatsblatter fur Augenheilkunde·2025
Same author

Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort.

Pediatric rheumatology online journal·2023
Same author

Phenotypic Characterization of Timothy Syndrome Caused by the <i>CACNA1C</i> p.Gly402Ser Variant.

Circulation. Genomic and precision medicine·2023

関連する実験動画

Updated: Jan 18, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.6K

小児科における川崎病

Sabrina Bressieux-Degueldre1, Katerina Theodoropoulou2, Alain Lefèvre-Utile3

  • 1Unité de cardiologie pédiatrique, Service de pédiatrie, Département femme-mère-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne.

Revue medicale suisse
|January 16, 2026
PubMed
まとめ

川崎病は幼少期に見られる急性血管炎であり、未治療の場合、冠動脈に問題を引き起こす可能性があります。ガイドラインの改訂は、早期診断と治療を支援し、罹患した子供たちの予後を改善します。

キーワード:
川崎病小児血管炎冠動脈ガイドラインスイス

さらに関連する動画

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.4K

関連する実験動画

Last Updated: Jan 18, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.6K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.4K

科学分野:

  • 小児科
  • リウマチ科
  • 心臓病学

背景:

  • 川崎病は、小児における後天性心疾患の主な原因である。
  • 未治療の川崎病は、冠動脈瘤の有意なリスク（25%）を伴う。
  • 最近のヨーロッパおよび北米のガイドライン更新は、診断および治療戦略に影響を与える。

研究 の 目的:

  • 川崎病の診断および管理ガイドラインの更新を要約する。
  • フランス語圏スイスにおける川崎病管理の主要な実践を強調する。
  • 難治性症例の治療および冠動脈合併症の予防における進歩について論じる。

主な方法:

  • 現在のヨーロッパおよび北米の川崎病ガイドラインのレビュー。
  • 臨床症状および発熱期間に基づく診断基準の分析。
  • 早期治療決定を導くための高リスク冠動脈基準の評価。

主要な成果:

  • 診断は、完全型の場合、発熱から4日以内の臨床症状（皮膚、粘膜、リンパ）の組み合わせに依存する。
  • 高リスク冠動脈基準は、迅速な治療を開始するために重要である。
  • 難治性疾患および冠動脈合併症の予後は、免疫療法および心臓ケアの進歩により改善されている。

結論:

  • 更新された基準に基づく早期診断と治療は、川崎病における冠動脈異常の予防に不可欠である。
  • 免疫調節療法および心臓療法を含む現在の治療戦略は、複雑な症例に対してより良い予後を提供する。
  • 更新されたガイドラインおよび地域の実践への準拠は、フランス語圏スイスにおける最適な患者ケアの鍵である。